May 22, 2020
U.S. FDA OKs Takeda’s Alunbrig for rare and serious lung cancer patients
Takeda’s Alunbrig long-Term results from the phase 3 ALTA 1L trial established Alunbrig as a superior first-line treatment compared to crizotinib for people with ALK+ metastatic NSCLC, including those with brain metastases.